Rajagopalan K, et al. - Given the established safety and efficacy of indacaterol 27.5 µg/glycopyrrolate 15.6 µg (IND/GLY 27.5/15.6 µg), researchers evaluated its cost-effectiveness in comparison to other long-acting COPD maintenance therapies. They constructed a Markov model from the US payer perspective. Health states were defined as mild (post-bronchodilator FEV1 ≥80% of predicted), moderate (50% ≤FEV1 <80% of predicted), severe (30% ≤FEV1 <50% of predicted), and very severe (FEV1 <30% of predicted) COPD. With a 5-year time horizon, this model identified IND/GLY 27.5/15.6 µg as cost-effective treatment option for patients with moderate to severe COPD.